Dmitry Vinogradov
J.P. Morgan has initiated coverage of gene therapy developer Neurogene (NGNE) with an Overweight recommendation, highlighting its lead program NGN-401 targeting a rare neurodevelopmental disorder known as Rett syndrome.
Analyst Priyanka Grover’s bullish view came at a time when shares